公开(公告)号：US20240239879A1

公开(公告)日：2024-07-18

申请号：US18440895

申请日：2024-02-13

Applicant: Xencor, Inc.

Inventor： Aaron Keith Chamberlain ,  Bassil Dahiyat ,  John R. Desjarlais ,  Sher Bahadur Karki ,  Gregory Alan Lazar

IPC: C07K16/18 ,  A61K39/00 ,  C07K14/715 ,  C07K16/08 ,  C07K16/22 ,  C07K16/24 ,  C07K16/28 ,  C07K16/32 ,  C07K16/42

CPC classification number: C07K16/18 ,  C07K14/7151 ,  C07K16/082 ,  C07K16/22 ,  C07K16/241 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/2893 ,  C07K16/2896 ,  C07K16/32 ,  C07K16/4291 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/90 ,  C07K2319/30 ,  Y02A50/30

Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.

公开(公告)号：US11981744B2

公开(公告)日：2024-05-14

申请号：US18067948

申请日：2022-12-19

Applicant: AMUNIX PHARMACEUTICALS, INC.

Inventor： Volker Schellenberger ,  Fan Yang ,  Desiree Thayer ,  Bee-Cheng Sim ,  Chia-Wei Wang

IPC: C07K16/30 ,  A61P35/00 ,  C07K14/00 ,  C07K16/28 ,  C12N5/09 ,  A61K38/00 ,  A61K39/00

CPC classification number: C07K16/30 ,  A61P35/00 ,  C07K14/00 ,  C07K16/2809 ,  C12N5/0693 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/572 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/60 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/01 ,  C07K2319/035 ,  C07K2319/21 ,  C07K2319/30 ,  C07K2319/31 ,  C07K2319/50 ,  C12N2523/00

Abstract: The present invention relates to bispecific chimeric polypeptide assembly compositions comprising bulking moieties linked to binding domains by cleavable release segments that, when cleaved are capable of concurrently binding effector T cells with targeted tumor or cancer cells and effecting cytolysis of the tumor cells or cancer cells. The invention also provides compositions and methods of making and using the cleavable chimeric polypeptide assembly compositions.

公开(公告)号：US11932685B2

公开(公告)日：2024-03-19

申请号：US17079299

申请日：2020-10-23

Applicant: Xencor, Inc.

Inventor： Aaron Keith Chamberlain ,  Bassil Dahiyat ,  John R. Desjarlais ,  Sher Bahadur Karki ,  Gregory Alan Lazar

IPC: C07K16/00 ,  A61K39/395 ,  C07H21/04 ,  C07K14/715 ,  C07K16/08 ,  C07K16/18 ,  C07K16/22 ,  C07K16/24 ,  C07K16/28 ,  C07K16/32 ,  C07K16/42 ,  C12N1/20 ,  C12N5/00 ,  C12N5/16 ,  C12N15/00 ,  A61K39/00

CPC classification number: C07K16/18 ,  C07K14/7151 ,  C07K16/082 ,  C07K16/22 ,  C07K16/241 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/2893 ,  C07K16/2896 ,  C07K16/32 ,  C07K16/4291 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/90 ,  C07K2319/30 ,  Y02A50/30

Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.

公开(公告)号：US11890354B2

公开(公告)日：2024-02-06

申请号：US16892973

申请日：2020-06-04

Applicant: CytomX Therapeutics, Inc.

Inventor： Henry Bernard Lowman ,  Luc Roland Desnoyers ,  Shouchun Liu ,  James William West ,  Jason Gary Sagert ,  Olga Vasiljeva ,  Elizabeth-Edna Mary Menendez

IPC: A61K39/00 ,  C07K16/00 ,  A61K49/00 ,  C07K16/28 ,  A61K47/68 ,  A61K39/395 ,  C07K16/30 ,  G01N33/574 ,  G01N33/58 ,  G01N33/68

CPC classification number: A61K49/0058 ,  A61K39/3955 ,  A61K47/6803 ,  A61K47/6849 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/30 ,  G01N33/57492 ,  G01N33/58 ,  G01N33/6872 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2317/94 ,  G01N2333/71

Abstract: The invention relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

公开(公告)号：US11865135B2

公开(公告)日：2024-01-09

申请号：US16466927

申请日：2017-12-05

Applicant: Innate Biotherapeutics, LLC

Inventor： Gabriel Oscar Reznik ,  John James Kane ,  James Michael Siedlecki ,  Zuzana Dostalova ,  Isabelle Sansal-Castellano ,  Ifat Rubin-Bejerano ,  Hua Miao ,  Eric Steven Furfine

IPC: A61K31/716 ,  A61K47/61 ,  C07K16/28 ,  C07K16/32

CPC classification number: A61K31/716 ,  A61K47/61 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/90

Abstract: The present invention encompasses embodiments in which a therapeutic antibody is conjugated to β-1,6-glucan oligomers. Thus, the present invention includes, among other things, compositions including a therapeutic antibody conjugated to one or more β-1,6-glucan oligomers. The present invention further includes, among other things, methods of making and/or using such β-1,6-glucan conjugates. In certain embodiments, a β-1,6-glucan conjugate of the present invention is useful as a therapeutic or in a method of therapy.

公开(公告)号：US20230312712A1

公开(公告)日：2023-10-05

申请号：US18174499

申请日：2023-02-24

Applicant: Alector LLC

Inventor： Tina SCHWABE ,  Eric BROWN ,  Philip KONG ,  Ilaria TASSI ,  Seung-Joo LEE ,  Arnon ROSENTHAL ,  Robert PEJCHAL ,  Nels P. NIELSON

IPC: C07K16/28 ,  A61P25/28

CPC classification number: C07K16/2803 ,  A61P25/28 ,  C07K2317/71 ,  C07K2317/90 ,  C07K2317/75 ,  C07K2317/76 ,  A61K2039/505

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US20230287134A1

公开(公告)日：2023-09-14

申请号：US18153181

申请日：2023-01-11

Applicant: UCB BIOPHARMA SRL

Inventor： Helene Margaret FINNEY ,  Stephen Edward RAPECKI ,  Kerry Louise TYSON ,  Michael John WRIGHT

IPC: C07K16/28 ,  C07K16/18

CPC classification number: C07K16/289 ,  C07K16/18 ,  C07K16/2803 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/24 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/35 ,  C07K2317/64 ,  C07K2317/624

Abstract: The present disclosure relates to constructs, such as antibody molecules comprising a binding domain specific to CD45, said binding domain comprising SEQ ID NO: 1, 2, 3 and/or SEQ ID NO: 4, 5 and 6. The disclosure also extends to pharmaceutical compositions comprising said constructs and use of the constructs/compositions in treatment.

公开(公告)号：US20230287117A1

公开(公告)日：2023-09-14

申请号：US17961442

申请日：2022-10-06

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Samuel Davis ,  Eric Smith ,  Tong Zhang ,  Supriya Patel

IPC: C07K16/28

CPC classification number: C07K16/2809 ,  C07K16/2803 ,  C07K16/2887 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/71 ,  C07K2317/732 ,  C07K2317/90

Abstract: The invention provides antibody heavy chain constant regions with a hinge region modified to reduce binding to Fcy receptors. The modification occurs within positions 233-236 by replacement of natural residues by glycine(s) and/or deletion(s). Such modifications can reduce binding of an antibody bearing such a constant region to Fcy receptors to background levels. The constant regions can be incorporated into any format of antibody or Fc fusion protein. Such antibodies or fusion proteins can be used in methods of treatment, particularly those in which the mechanisms of action of the antibody or Fc fusion protein is not primarily or at all dependent on effector functions, as is the case when an antibody inhibits a receptor-ligand interaction or agonizes a receptor.

公开(公告)号：US11726094B2

公开(公告)日：2023-08-15

申请号：US16919449

申请日：2020-07-02

Applicant: 4TEEN4 PHARMACEUTICALS GMBH

Inventor： Andreas Bergmann

IPC: G01N33/58 ,  G01N33/574 ,  G01N33/68 ,  C07K16/40 ,  G01N33/543 ,  A61K39/00

CPC classification number: G01N33/581 ,  C07K16/40 ,  G01N33/54306 ,  G01N33/574 ,  G01N33/6854 ,  G01N33/6893 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/90 ,  G01N2333/948 ,  G01N2800/24 ,  G01N2800/26 ,  G01N2800/325 ,  G01N2800/347 ,  Y02A50/30

Abstract: The present invention is directed to methods for determining active DPP3 in a bodily fluid sample, an assay or kit for determining active DPP3 in a bodily fluid sample, a method for diagnosing a disease or condition in a subject accompanied by or related to necrotic processes and methods of treating or preventing said disease.

公开(公告)号：US11690912B2

公开(公告)日：2023-07-04

申请号：US17058508

申请日：2019-05-29

Applicant: Abcentra, LLC

Inventor： Bertrand C. Liang ,  Stacey Ruiz ,  Christopher John Farina

IPC: A61K39/395 ,  A61P29/00 ,  A61P9/00 ,  G01N33/50 ,  C07K16/18 ,  A61P9/10 ,  C07K14/775 ,  A61K45/06 ,  A61K39/00 ,  G01N33/53

CPC classification number: A61K39/3955 ,  A61P9/10 ,  A61P29/00 ,  C07K16/18 ,  G01N33/50 ,  A61K45/06 ,  A61K2039/505 ,  C07K14/775 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/90 ,  G01N33/53

Abstract: Compositions and methods for treating rheumatoid arthritis and/or accelerated atherosclerosis are provided, including an inhibitor of oxidized or malondialdehyde-modified low density lipoprotein (LDL) for administration to a subject. Exemplary inhibitors of oxidized LDL include an anti-oxidized LDL antibody, which results in a reduction in the secretion of pro-inflammatory cytokine from primary monocyte in vitro and the plasma cytokine level of inflammatory cytokine in vivo.